Breaking News, Collaborations & Alliances

Vectura Signs Agreement with Aerami Therapeutics

Will support the development of imatinib for the treatment of Pulmonary Arterial Hypertension

By: Contract Pharma

Contract Pharma Staff

Vectura Group plc, an inhalation CDMO, has signed of a global license and development agreement with Aerami Therapeutics Inc. for inhaled imatinib (VR325) for the treatment of Pulmonary Arterial Hypertension.   Aerami will be responsible for the overall development and commercialization of inhaled imatinib, with Vectura providing development services expertise and a license to its Fox mesh nebuliser technology.   Under the partnership, Vectura will receive development fees, revenue from the prov...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters